Best Integrated Utility Stocks To Own Right Now

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings' unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Grand Canyon Education (Nasdaq: LOPE  ) , whose recent revenue and earnings are plotted below.

Top 10 Recreation Companies To Buy For 2015: Ardonblue Ventures Inc (ARB)

Ardonblue Ventures Inc., formerly August Metal Corporation, is a Canada-based company engaged in the business of acquiring, exploring and evaluating mineral resource properties. Las Lajas Project consists of approximately seven contiguous mining concessions and is located in Southern Sonora State, Mexico. The concessions are owned by Minera Goldzone SA de CV a wholly owned subsidiary of Goldzone Exploration Inc. Las Lajas has access and infrastructure as it is located approximately 15 kilometers north of the city of Navojoa. The Thurlow Property occupies the central part of the Doratha Morton gold trend, located on British Columbia�� southwestern coast near Phillips Arm. The Property consists of approximately nine crown granted mineral claims covering a total of approximately 142.61hectares. Advisors' Opinion:

• [By Rich Duprey]

  International media and marketing shop Arbitron� (NYSE: ARB  ) �announced yesterday�its second-quarter dividend of $0.10 per share, the same rate it's always paid since 2005

Best Integrated Utility Stocks To Own Right Now: Samsung Electronics Co Ltd (SSNLF)

Samsung Electronics Co., Ltd. mainly engaged in the production of consumer electronic products. It operates in two divisions: DMC division, which is divided into consumer electronics (CE) and information technology & mobile communications (IM) businesses, as well as DS division, which is divided into semiconductor and liquid crystal display (LCD) businesses. Its CE business engages in the production of color televisions (CTVs), monitors, air conditioners, refrigerators and others. Its IM business engages in the production of printers, computers, handhold phones (HHPs) such as feature phones, smart phones and others, and network systems, among others. Its semiconductor business engages in the production of semiconductors, such as memories, system large scale integrated circuits (LSIs) and others. Its LCD business engages in the production of thin film transistor (TFT) LCDs and organic light-emitting diodes (OLEDs), among others. Advisors' Opinion:

• [By Rahul Chattaraj]

  BlackBerry has a very different target audience than that of Apple, Samsung (SSNLF) or other players using the Google (GOOG) Android OS. While these players are competing against each other in the smartphone space, BlackBerry is eying the corporate enterprises. The Canadian phonemaker is not just focusing on offering smartphones, rather is focusing on offering an integrated, safe and secured host of services. This being clear, it is also clear that the target audiences of the Typo cases and of that of BlackBerry are not the same. BlackBerry users can�� use the cases on the BlackBerry devices and thus BlackBerry is not going to suffer from loss of sale.

• [By WWW.DAILYFINANCE.COM]

  Michael Sohn/AP The smartwatch craze appears to have come and gone without changing the world. Pebble -- the Kickstarter-funded company the kicked off the revolution of Web-tethered wristwatches -- has been a fringe player at best. Samsung (SSNLF) -- the world's largest maker of smartphones -- hasn't had a lot of success with its Galaxy Gear line, now in its second incarnation. Silent through this ho-hum movement is Apple (AAPL), the one company that many figured would be the game changer in this once-promising niche of wearable computing. There was some hope that Apple would use its Worldwide Developers Conference earlier this month to announce its entry into the smartwatch market and woo top developers to start coding applications for the iWatch. It didn't happen. However, shortly after the conference closed, reports began to surface about Apple entering the market in October. This will be a big story if it happens, but it may be too late. Rock Around the Clock The smartwatch was supposed to change everything. Pebble's initial shortcomings -- it didn't make calls and ran only a limited number of apps -- seemed to have been addressed when Samsung and Qualcomm (QCOM) introduced fancier fare. However, with Samsung limiting its devices to work only with select Galaxy devices and Qualcomm's Toq coming up short due to a lack of voice commands and native input options, we find ourselves with a revolution that appears stuck in the mud. Apple could change that, but the world's leading consumer tech company faces an uphill battle to overcome obstacles that have soured the market's enthusiasm for timepieces with computing features. Time is Ticking Away Apple investors are hungry for innovation in a new product category. Mac sales have stalled; the iPod has been declining in popularity for a couple of years; and even the iPad saw a surprising drop in sales in the latest quarter. The iPhone continues to be the workhorse for Apple, and a little diversification wou

Best Integrated Utility Stocks To Own Right Now: Blackstone Mortgage Trust Inc (BXMT)

Blackstone Mortgage Trust, Inc., formerly Capital Trust, Inc. is a self-managed, real estate finance and investment management company that specializes in credit sensitive financial products. The Company�� investment programs are focused on loans and securities backed by commercial real estate assets. The Company invests for its own account and for third parties through a series of investment management vehicles. Capital Trust, Inc. conducts its operations as a real estate investment trust (REIT). In December 2012, the Company announced that an affiliate of Blackstone completed the previously announced acquisition of its investment management business, operated through its subsidiary, CT Investment Management Co., LLC (CTIMCO).

As of December 31, 2009, its $1.8 billion of interest earning assets were comprised of $1.1 billion of loans receivable, including $17.5 million of loans classified as held-for-sale, and $715.2 million of securities. These include 20 impaired loans with an aggregate net book value of $131.0 million ($608.4 million gross carrying value, net of $477.4 million of reserves), and 11 impaired securities with an aggregate net book value of $27.4 million ($145.7 million gross carrying value, against which it has recorded other-than-temporary impairments of $118.3 million).

Advisors' Opinion:

• [By GuruFocus]

  George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

Best Integrated Utility Stocks To Own Right Now: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By Rich Duprey]

  Having already purchased $1.8 billion worth of stock so far this year and having exhausted its existing $2.5 billion share repurchase program, biopharmaceutical Celgene (NASDAQ: CELG  ) announced this morning�that its board of directors has authorized a new�$3 billion buyback program.

• [By Ben Levisohn]

  Werber and Eckhard’s favorites include Gilead (GILD) and Celgene (CELG), and they find the “risk/reward…compelling” in Medivation (MDVN) and Tesaro (TSRO).

• [By Keith Speights]

  Celgene (NASDAQ: CELG  ) appears to be keeping its momentum rolling. The biotech reported solid first-quarter results before the market opened on Wednesday. Shares fluctuated slightly in early trading. Here are the highlights.

• [By Sean Williams]

  Thursday, April 25
  

  Biogen Idec (NASDAQ: BIIB  ) : Biogen is so hot right now, I'd highly recommend using oven mitts when handling shares. Over the past quarter, Biogen announced the purchase of the remaining global rights to multiple sclerosis drug Tysabri from Elan�for $3.25 billion in cash and had the Food and Drug Administration approve its revolutionary new MS-drug Tecfidera. I don't believe Biogen Idec's first-quarter results will have much bearing on its share price so much as its forward guidance. This will be the first time Wall Street gets a glimpse at the growth Biogen expects from Tecfidera sales as well as owning the full global rights to Tysabri. Pay attention to its full-year EPS forecast and anything the company has to say regarding its 2014 growth estimates. Celgene (NASDAQ: CELG  ) : Celgene's CEO, Robert Hugin, made some very bold claims at the JPMorgan Healthcare Conference in January that his company would be able to triple revenue and double EPS growth by 2017 based solely on organic growth. Consider this quarter the first test of that assertion. Things have definitely moved in Celgene's favor, with Abraxane gaining additional indications in cancer treatment and Revlimid sales running strong. However, it'll need to gain approval of Apremilast to treat psoriasis if it hopes to achieve its lofty growth targets. Following Celgene's huge first-quarter run, the company's guidance here will be everything, so focus all of your attention on that, and any comments with regard to the advancement of Apremilast. Alexion Pharmaceuticals (NASDAQ: ALXN  ) : Having seen Affymax�shares implode because of a recall, I'm always concerned about companies whose entire pipeline lives and dies off one drug. Alexion's Soliris is a billion-dollar blockbuster, but its entire pipeline involves the use of Soliris in one indication or another. Therefore, my big focus in Alexion's first-quarter report will be if it can top EP

Best Integrated Utility Stocks To Own Right Now: Roma Financial Corporation(ROMA)

Roma Financial Corporation operates as a holding company for Roma Bank and RomAsia Bank that provide traditional retail banking services primarily in New Jersey. The company offers current deposit products, including checking and savings accounts, money market, certificates of deposit accounts, and individual retirement accounts. It also provides one-to four-family residential mortgage loans; multi-family and commercial mortgage loans; construction loans; commercial business loans; and consumer loans comprising home equity loans and lines of credit. In addition, the company sells title insurance; performs title searches; and provides real estate settlement and closing services. It operates 23 branch offices in Mercer, Burlington, Camden, and Ocean Counties, New Jersey; and 2 branches in Monmouth Junction and Edison, New Jersey. The company was founded in 1920 and is headquartered in Robbinsville, New Jersey.

Advisors' Opinion:

• [By Tim Melvin]

  He also pointed out that the approaching completion of Roma Financial (ROMA) and Investors Bancorp (ISBC) has some interesting implications for bank stock investors. Both are mutual holding companies, and the newly formed bank is expected to complete the process and do a second-step conversion offering. That will be a fairly large deal, much larger than most second-step offerings, as the combined banks should be somewhere around $3 billion in market cap. There will be larger investment banks involved, complete with road shows and institutional meetings to promote the deal. The attention could well cause a revaluation of the mutual holding company and converted thrift sector of the banking market.

Best Integrated Utility Stocks To Own Right Now: Exide Technologies (XIDEQ)

Exide Technologies, incorporated on November 23, 1966, is engaged in stored electrical energy solutions, and is a manufacturer and supplier of lead-acid batteries for transportation and industrial applications in the worldwide. Exide operates in four business segments: Transportation Americas, Transportation Europe and ROW, Industrial Energy Americas, and Industrial Energy Europe and ROW. The Company�� operations in the Americas as well as Europe and Rest of World (ROW) represented approximately 42% and 58%, respectively, during the fiscal year ended March 31, 2013 (fiscal 2013), net sales.

Transportation

The Company�� transportation batteries include starting lighting and ignition (SLI) batteries for cars, trucks, off-road vehicles, agricultural and construction vehicles, motorcycles, recreational vehicles, marine, and other applications including Micro-hybrids. The Company�� principal batteries sold in the transportation markets are represented by brands: Exide, Exide Extreme, Exide NASCAR Select, Centra, DETA, Orbital, Fulmen, and Tudor, as well as other brands under various private labels. The market for transportation batteries is divided between sales to aftermarket customers and original equipment manufacturers (OEMs). Transportation segments represented approximately 61% of the Company�� net sales in fiscal 2013. Within the transportation segments, aftermarket and OEM net sales, including original equipment service (OES) represented approximately 72.1% and 27.9% of fiscal 2013 net sales, respectively.

Some of the Company�� aftermarket customers include Pep Boys, Bosch, Tractor Supply, Canadian Tire, ADI, ATR International, and GroupAuto International. In addition, the Company is also a supplier of authorized replacement batteries for OEMs including the BMW Group, Fiat Group, Honda, Iveco, John Deere, PSA Group, Scania, Volvo Trucks, Toyota, Volkswagen Group, Renault-Nissan, PACCAR, and many others. Some of the Company�� OEM customers include t! he BMW Group, Fiat Group, International Truck & Engine, the PSA group (Peugeot S.A./Citroen), Case/New Holland, John Deere, Renault, Nissan, Scania, Volvo Trucks, Volkswagen Group, Chrysler, Toyota, Jaguar, Land Rover, among others.

In the Americas, the Company sells aftermarket transportation products through various distribution channels, including mass merchandisers, auto parts outlets, wholesale distributors, and battery specialists. The Company sells its OEM transportation replacement products principally through dealer networks. The Company�� Americas operations include a network of 74 branches which sell and distribute batteries and other products to the Company�� distributor channel customers, battery specialists, national account customers, retail stores, and OEM dealers. In addition, these branches collect spent batteries for the Company�� recycling facilities. These operations supply recycled lead for approximately 75 to 80% of Exide�� Transportation and Industrial Energy products manufactured in North America. The recycling facilities also recover and recycle battery acid as well as plastic materials that are used to produce new battery covers and cases.

In Europe and ROW, the Company sells OEM batteries to the light vehicle, light commercial vehicle and commercial vehicle industries. The commercial vehicle industry includes truck manufacturers as well as construction and agriculture vehicle manufacturers. Exide supplies its OEM batteries directly to the assembly plants of its customers. The Company also delivers service and replacement batteries into this segment. Those are either distributed by the OEM customers themselves or delivered directly to the service points through the Exide logistics network. The Company also supplies advanced lead-acid batteries for microhybrid vehicles equipped with carbon dioxide reducing technologies such as Start & Stop with and without regenerative braking systems. It sells Europe and ROW aftermarket batteries primarily th! rough aut! omotive parts and battery wholesalers, mass-merchandisers, auto centers, service installers, and oil companies. Battery specialists sell and distribute batteries to a network of automotive parts retailers, service stations, independent retailers, and garages throughout Europe.

The Company competes with Johnson Controls, Inc. and East Penn Manufacturing.

Industrial Energy

The Company�� Industrial Energy segments supply both motive power and network power applications. Motive power batteries are used in the material handling industry for electric forklift trucks, and in other industries, including floor cleaning machinery, powered wheelchairs, railroad locomotives, mining, and the electric road vehicles market. The battery technologies for the motive power markets include flooded flat plate products, tubular plate products, absorbed glass mat (AGM) products, and gel electrolyte products. The Company also offers a complete range of battery chargers and related equipment for the operation and maintenance of battery-powered vehicles. Network power batteries are used to provide back-up power for use with telecommunications systems, computer installations or data centers, hospitals, air traffic control systems, security systems, utilities, railway and military applications. Telecommunications applications include central and local switching systems, satellite stations, wireless base stations and mobile switches, optical fiber repeating boxes, cable television transmission boxes, and radio transmission stations. The Company�� strongest network power battery brands, Absolyte and Sonnenschein, offer customers the choice of AGM or gel electrolyte valve regulated battery technologies and deliver among the highest energy and power densities in their class.

In the Americas, the Company distributes motive power products and services through multiple channels. These include sales and service locations owned by the Company that are augmented by a network of indep! endent ma! nufacturers��representatives. The Company serves a wide range of customers including OEM suppliers of lift trucks, industrial companies, retail distributors, warehousing companies, and manufacturers. Motive power customers in the Americas include Toyota, MCFA, NACCO, Sears, Toyota, Walmart, and Target. The Company distributes network power products and services through sales and service locations owned by the Company augmented by a network of independent manufacturers��representatives. The Company�� primary network power customers in the Americas include AT&T, APC, Emerson Electric, and Verizon Wireless.

The Company distributes motive power products and services in Europe through in-house sales and service organizations and utilizes distributors and agents for the export of products from Europe to ROW countries. Motive power products in Europe are also sold to a wide range of customers in the aftermarket, ranging from industrial companies and retail distributors to small warehousing and manufacturing operations. Motive power batteries are also sold in complete packages, including batteries, chargers, and increasingly through on-site service. The Company�� OEM motive power customers include Toyota Material Handling, the KION Group, and Jungheinrich. The Company distributes network power products and services in Europe and batteries and chargers in Australia and New Zealand through in-house sales and service organizations. In Asia, products are distributed through independent distributors. The Company utilizes distributors, agents, and direct sales to export products from Europe and North America to ROW. The Company�� primary Network Power customers in Europe and ROW include Deutsche Telecom, Alcatel, Emerson Electric, Ericsson and Siemens Nokia Networks.

The Company competes with EnerSys Inc., East Penn Manufacturing, Hoppecke, MIDAC, GS/Yuasa, Shinkobe and C&D Technologies.

Advisors' Opinion:

• [By Rich Duprey]

  A real car wreck on the horizon
  Already crashing and burning was lead-acid battery maker Exide Technologies (NASDAQOTH: XIDEQ  ) , which confirmed it had hired a restructuring specialist to help it cope with is financial situation ahead of some of its debt maturing this fall. It's shares fell almost 48% on the news.

Best Integrated Utility Stocks To Own Right Now: Model N Inc (MODN)

Model N, Inc., incorporated on December 14, 1999, is a provider of revenue management solutions for the life science and technology industries. The Company�� solutions enable its customers to maximize revenues and reduce revenue compliance risk by transforming their revenue lifecycle from a series of tactical, disjointed operations into a strategic end-to-end process. The Company�� customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. Its solutions include two complementary suites of software applications, Revenue Management Enterprise and Revenue Management Intelligence. On January 18, 2012, the Company acquired certain assets of LeapFrogRx, Inc. (LeapFrogRx), a privately held cloud-based analytics solution provider for the pharmaceutical industry.

The Company provides solutions that span the organizational and operational boundaries of functions such as sales, marketing and finance, and serve as a system of record for key revenue management processes including pricing, contracts, rebates and regulatory compliance. Its application suites are purpose-built for the life science and technology industries and are designed to work with enterprise resource planning (ERP) and customer relationship management (CRM) applications that do not typically provide revenue management capabilities by enabling real-time pricing, managing contracts and automating channel incentives management, including rebates.

Revenue Management Enterprise suite

A broad set of transactional applications that serve as a system of record for, and automate the execution of revenue management processes such as incentive and rebate management, pricing and contracting. This suite includes its Price Management, Deal Management, Contract Management, Incentive and Rebate Management and Regulatory Compliance Management applications, which can be purchased together as a suite or as separate stand-alone applications.

Revenue Management Intelligence suite

A broad set of intelligence applications that provide the analytical insights to define and optimize revenue management strategies. This suite includes its Price Strategy, Brand Strategy, Channel Strategy, Managed Markets Strategy and International Reference Pricing applications, which can be purchased together as a suite or as separate stand-alone applications.

Advisors' Opinion:

• [By Rick Munarriz]

  I went out on a limb last week, and now it's time to see how that decision played out.

  I predicted that Model N (NYSE: MODN  ) would post a smaller loss than analysts were expecting. The provider of revenue management solutions has been a dud since going public nearly a year ago, but one thing it has consistently done is post a smaller deficit than what the pros are forecasting. Wall Street was settling for a loss of $0.12 a share, and Model N sported only $0.03 a share in red ink. The stock soared 19% on Tuesday after the better-than-expected report. I was right. After more than a year of predicting that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average � (DJINDICES: ^DJI  ) , I mixed things up two weeks ago. I simply predicted that the Dow would bounce back after plunging 3.5% and 1.1% over the prior two weeks. I repeated the call this time around, and the Dow responded with a hearty 2.3% gain. I was right.� My final call was for LeapFrog (NYSE: LF  ) to beat Wall Street's income estimates in its latest quarter. The maker of electronic learning toys has been routinely beating Wall Street projections over the past year. I was banking on a repeat performance, but it wasn't to be. LeapFrog merely broke even on a sharper drop in revenue than expected. Analysts had been braced for a profit of $0.14 a share. I was wrong.

  Two out of three? I can do better than that. Let me once again whip out my trusty, dusty, and occasionally accurate crystal ball to make three calls that may play out over the next few trading days.

• [By Lee Jackson]

  Model N Inc. (NYSE: MODN) develops applications, such as managed care and government pricing, for life science companies and channel incentives based on design wins for technology companies. The company’s customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. The company had a recent initial public offering (IPO) that traded as high as $24.80 before badly missing earnings and being taken to the woodshed. Deutsche Bank still rates it as a stock to buy and has a $12 price target. The consensus target is at $15. The stock closed Friday at $9.88.